1-2 of 2
Ian E. Krop
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A. Hurvitz, Shanu Modi, Fabrice Andre, Ian E. Krop, Xavier Gonzàlez Farré, Benoit You, Cristina Saura, Sung-Bae Kim, Cynthia R. Osborne, Rashmi K. Murthy, Lorenzo Gianni, Toshimi Takano, Yali Liu, Jillian Cathcart, Caleb Lee, Christophe Perrin
Journal: Cancer Discovery
Cancer Discov (2022) 12 (12): 2754–2762.
https://doi.org/10.1158/2159-8290.CD-22-0837
Published: 02 December 2022
View article titled, Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Open the PDF for Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis in another window
Includes: Supplementary data
Journal Articles

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Otto Metzger Filho, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell'Orto, Leila Russo, Tari A. King, Kornelia Polyak, Franziska Michor, Eric P. Winer, Ian E. Krop
Journal: Cancer Discovery
Cancer Discov (2021) 11 (10): 2474–2487.
https://doi.org/10.1158/2159-8290.CD-20-1557
Published: 01 October 2021
View article titled, Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Open the PDF for Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab in another window
Includes: Supplementary data